INB-400

N/A

Report date: 2023/04/26 10:15:39

Base Information

Drug NameINB-400

Drug Alias NameDeltEx Allo DRI INB-400Modified DeltEx allogeneic candidate INB-400Gamma-Delta (γδ)T Cell Therapy INB-400γδT Cell Therapy INB-400INB-400

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesIN8BIO Inc

China Registration ClassN/A

Develop Information

Active CompaniesIN8BIO Inc

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A